Overview

A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease

Status:
Terminated
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the effectiveness and safety of 2 years of treatment with galantamine as compared with placebo of patients who have mild to moderately severe Alzheimer's disease (AD).
Phase:
Phase 3
Details
Lead Sponsor:
Janssen Research & Development, LLC
Treatments:
Galantamine